PL2493466T3 - Nowe przeciwguzowe zastosowanie kabazytakselu - Google Patents

Nowe przeciwguzowe zastosowanie kabazytakselu

Info

Publication number: PL2493466T3
Authority: PL; Poland
Prior art keywords: cabazytaxel; tumble; application; new anti; new
Prior art date: 2009-10-29

Application number

PL10782039T

Other languages

English (en)

Inventor

Sunil Gupta

Original Assignee

Sanofi Mature Ip

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-29

Filing date

2010-10-27

Publication date

2021-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-27 Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip

2021-11-15 Publication of PL2493466T3 publication Critical patent/PL2493466T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)

PL10782039T 2009-10-29 2010-10-27 Nowe przeciwguzowe zastosowanie kabazytakselu PL2493466T3 (pl)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US25616009P	2009-10-29	2009-10-29
US29390310P	2010-01-11	2010-01-11
US35583410P	2010-06-17	2010-06-17
US35588810P	2010-06-17	2010-06-17
US36992910P	2010-08-02	2010-08-02
US38393310P	2010-09-17	2010-09-17
US38996910P	2010-10-05	2010-10-05
PCT/IB2010/054866 WO2011051894A1 (en)	2009-10-29	2010-10-27	Novel antitumoral use of cabazitaxel
EP10782039.1A EP2493466B1 (en)	2009-10-29	2010-10-27	Novel antitumoral use of cabazitaxel

Publications (1)

Publication Number	Publication Date
PL2493466T3 true PL2493466T3 (pl)	2021-11-15

Family

ID=43567614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10782039T PL2493466T3 (pl)	2009-10-29	2010-10-27	Nowe przeciwguzowe zastosowanie kabazytakselu

Country Status (31)

Country	Link
US (8)	US8927592B2 (pl)
EP (1)	EP2493466B1 (pl)
JP (2)	JP5566466B2 (pl)
KR (1)	KR101712231B1 (pl)
CN (1)	CN102770131A (pl)
AR (1)	AR078824A1 (pl)
AU (4)	AU2010310986A1 (pl)
BR (1)	BR112012011457A2 (pl)
CA (1)	CA2779009A1 (pl)
CR (1)	CR20120204A (pl)
DK (1)	DK2493466T3 (pl)
EA (1)	EA024186B1 (pl)
EC (1)	ECSP12011836A (pl)
ES (1)	ES2862340T3 (pl)
GT (1)	GT201200123A (pl)
IL (3)	IL219443A0 (pl)
MA (1)	MA33767B1 (pl)
MX (1)	MX336339B (pl)
MY (1)	MY164086A (pl)
NI (1)	NI201200071A (pl)
PE (1)	PE20121429A1 (pl)
PH (1)	PH12012500848A1 (pl)
PL (1)	PL2493466T3 (pl)
PT (1)	PT2493466T (pl)
SG (1)	SG10201810928SA (pl)
SV (1)	SV2012004192A (pl)
TN (1)	TN2012000188A1 (pl)
TW (2)	TWI533866B (pl)
UY (1)	UY32987A (pl)
WO (1)	WO2011051894A1 (pl)
ZA (1)	ZA201203123B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2926551A1 (fr)	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) *	2009-10-19	2012-03-15	Nagesh Palepu	Cabazitaxel formulations and methods of preparing thereof
JP5566466B2 (ja)	2009-10-29	2014-08-06	アバンテイス・フアルマ・エス・アー	カバジタキセルの新規の抗腫瘍的使用
KR20140018917A (ko) *	2011-04-12	2014-02-13	플러스 케미칼스, 에스.에이.	카바지탁셀의 고상 형태 및 이의 제조 방법
CN102503913B (zh) *	2011-10-20	2014-03-26	江苏红豆杉生物科技股份有限公司	直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013088335A1 (en)	2011-12-13	2013-06-20	Aventis Pharma S.A.	Crystalline form of cabazitaxel and process for preparing the same
WO2013111157A1 (en) *	2012-01-03	2013-08-01	Shilpa Medicare Limited	Process for preparing amorphous cabazitaxel
WO2014022237A1 (en) *	2012-07-31	2014-02-06	Yung Shin Pharm. Ind. Co., Ltd.	Amorphous cabazitaxel
TW201438714A (zh) *	2013-03-04	2014-10-16	Aventis Pharma Sa	卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP3258931B1 (en) *	2015-02-17	2020-08-12	Erasmus University Medical Center Rotterdam	Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) *	2015-05-13	2016-11-16	Aventis Pharma S.A.	Cabazitaxel and its use for treating cancer
EP3509569A1 (en)	2016-09-07	2019-07-17	Cadila Healthcare Limited	Sterile injectable compositions comprising drug micelles
US10195214B2 (en)	2017-03-01	2019-02-05	Corcept Therapeutics, Inc.	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
WO2018187786A1 (en) *	2017-04-07	2018-10-11	La Jolla Institute For Allergy And Immunology	Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
US20250017891A1 (en) *	2023-07-04	2025-01-16	Twi Pharmaceuticals, Inc.	Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en)	1989-10-13	1991-04-09	David Rubin	Method for increasing tumor sensitivity to chemotherapy
US5714512A (en)	1991-07-08	1998-02-03	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
US5698582A (en)	1991-07-08	1997-12-16	Rhone-Poulenc Rorer S.A.	Compositions containing taxane derivatives
US5750561A (en)	1991-07-08	1998-05-12	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
FR2698543B1 (fr)	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
FR2698871B1 (fr)	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2732340B1 (fr)	1995-03-27	1997-04-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ZA94128B (en)	1993-02-01	1994-08-19	Univ New York State Res Found	Process for the preparation of taxane derivatives and betalactam intermediates therefor
US5847170A (en)	1995-03-27	1998-12-08	Rhone-Poulenc Rorer, S.A.	Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en)	1995-03-27	2002-04-16	Aventis Pharma S.A.	Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (fr)	1995-03-27	1996-10-01	Aventis Pharma Sa	Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr)	1996-03-06	1998-04-03	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr)	1997-11-18	1999-12-17	Rhone Poulenc Rorer Sa	Procede de preparation de derives de la classe des taxoides
US6346543B1 (en)	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
CA2341191A1 (en)	1998-08-20	2000-03-02	Aventis Pharma S.A.	New use of taxoid derivatives
US6403634B1 (en)	1999-01-13	2002-06-11	Aventis Pharma S.A.	Use of taxoid derivatives
US20040126379A1 (en)	2002-08-21	2004-07-01	Boehringer Ingelheim International Gmbh	Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
DE50301051D1 (de)	2003-07-02	2005-09-29	Scheuten Glasgroep Venlo	Verfahren zur Herstellung einer Brandschutzverglasung
EP1498120A1 (en)	2003-07-18	2005-01-19	Aventis Pharma S.A.	Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr)	2003-09-19	2006-02-03	Aventis Pharma Sa	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en)	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
EP2395109A1 (en)	2004-12-08	2011-12-14	Aventis Pharmaceuticals Inc.	Method for measuring resistance or sensitivity to docetaxel
EP1700596A1 (en)	2005-03-09	2006-09-13	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.	Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es)	2006-01-20	2007-06-13	Eriochem Sa	Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr)	2007-10-10	2010-02-26	Aventis Pharma Sa	Nouvelles compositions a base de taxoides
FR2926551A1 (fr)	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en)	2008-10-02	2010-04-21	Institut Gustave Roussy	Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en)	2009-02-23	2016-08-30	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
EP2413901A4 (en)	2009-03-30	2015-05-06	Cerulean Pharma Inc	POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
FR2945211A1 (fr)	2009-05-06	2010-11-12	Sanofi Aventis	Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
JP5855568B2 (ja)	2009-09-15	2016-02-09	セルリアン・ファーマ・インコーポレイテッド	癌の治療法
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
JP5566466B2 (ja)	2009-10-29	2014-08-06	アバンテイス・フアルマ・エス・アー	カバジタキセルの新規の抗腫瘍的使用
US8686165B2 (en)	2009-11-04	2014-04-01	Emcure Pharmaceuticals Limited	Process for preparation of taxane derivatives
EP2503888A4 (en)	2009-11-23	2015-07-29	Cerulean Pharma Inc	POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
WO2011124669A1 (en)	2010-04-08	2011-10-13	Institut Gustave Roussy	Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en)	2010-04-13	2011-10-20	Amplyx Pharmaceuticals Inc.	Therapeutic agents having reduced toxicity
EP2558109A4 (en)	2010-04-16	2014-09-24	Bellicum Pharmaceuticals Inc	METHOD FOR TREATING HARD TUMORS
EP3093014A1 (en)	2015-05-13	2016-11-16	Aventis Pharma S.A.	Cabazitaxel and its use for treating cancer
EP3808345A1 (en)	2019-10-15	2021-04-21	Sanofi Mature IP	Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

2010
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-27 PH PH1/2012/500848A patent/PH12012500848A1/en unknown
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active Active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en not_active Ceased
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
2012
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
2023
- 2023-07-20 US US18/224,122 patent/US12453712B2/en active Active

Also Published As

Publication number	Publication date
US20150118182A1 (en)	2015-04-30
IL219443A0 (en)	2012-06-28
TW201127374A (en)	2011-08-16
EA201270606A1 (ru)	2013-01-30
JP2014196323A (ja)	2014-10-16
US8927592B2 (en)	2015-01-06
JP2013509394A (ja)	2013-03-14
ZA201203123B (en)	2013-06-26
US10583110B2 (en)	2020-03-10
US20240139146A1 (en)	2024-05-02
AU2016200598A1 (en)	2016-02-25
ES2862340T3 (es)	2021-10-07
AU2019203514A1 (en)	2019-06-06
AU2010310986A1 (en)	2012-06-14
UY32987A (es)	2011-05-31
EA024186B1 (ru)	2016-08-31
EP2493466A1 (en)	2012-09-05
TWI654975B (zh)	2019-04-01
JP6182510B2 (ja)	2017-08-16
ECSP12011836A (es)	2012-07-31
US20120301425A1 (en)	2012-11-29
IL250254A0 (en)	2017-03-30
US10716777B2 (en)	2020-07-21
NI201200071A (es)	2012-08-20
US12453712B2 (en)	2025-10-28
CN102770131A (zh)	2012-11-07
MA33767B1 (fr)	2012-11-01
US20200155497A1 (en)	2020-05-21
TN2012000188A1 (en)	2013-12-12
WO2011051894A1 (en)	2011-05-05
GT201200123A (es)	2013-11-07
AR078824A1 (es)	2011-12-07
PE20121429A1 (es)	2012-11-06
AU2017232227A1 (en)	2017-10-12
EP2493466B1 (en)	2021-03-10
IL267583A (en)	2019-08-29
MY164086A (en)	2017-11-30
MX2012005030A (es)	2012-12-05
US20190151278A1 (en)	2019-05-23
JP5566466B2 (ja)	2014-08-06
US20180125810A1 (en)	2018-05-10
CR20120204A (es)	2012-07-04
BR112012011457A2 (pt)	2016-05-03
US20150104411A1 (en)	2015-04-16
SV2012004192A (es)	2012-08-23
AU2017232227B2 (en)	2019-06-06
MX336339B (es)	2016-01-14
SG10201810928SA (en)	2019-01-30
TWI533866B (zh)	2016-05-21
TW201611831A (en)	2016-04-01
PH12012500848A1 (en)	2016-02-08
US20210169843A1 (en)	2021-06-10
CA2779009A1 (en)	2011-05-05
KR20120093986A (ko)	2012-08-23
KR101712231B1 (ko)	2017-03-03
PT2493466T (pt)	2021-03-29
DK2493466T3 (da)	2021-04-26

Publication	Publication Date	Title
PL2493466T3 (pl)	2021-11-15	Nowe przeciwguzowe zastosowanie kabazytakselu
SMT201600075B (it)	2016-04-29	Composto di diamminocarbossammide eterociclica
DOP2012000114A (es)	2012-08-15	Inhibidor bromodominio de benzodiazepina
IL225867B (en)	2018-07-31	Coelenterazine substrates
EP2518066A4 (en)	2013-07-03	NOVEL THROMBOCYTE AGGREGATION INHIBITOR
EP2399504A4 (en)	2012-12-05	DEVICE FOR INTRODUCING ENDOSCOPE
BR112012000657A2 (pt)	2016-11-16	novos azabicilohexanos
FI20095529L (fi)	2010-11-13	Probioottien uusi käyttö
EP2349335A4 (en)	2012-02-08	LEVETIRACETAM IMMUNOASSAYS
UY33156A (es)	2011-07-29	Nuevos compuestos tienopirrol
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
DK2453858T3 (da)	2014-11-03	Fremgangsmåde
SMT201500268B (it)	2016-01-08	Derivato di 5-idrossipirimidin-4-carbossammide
LT2506840T (lt)	2021-06-25	Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DOP2011000348A (es)	2012-01-15	Construcciones casb7439
EP2380788A4 (en)	2012-09-26	SAFETY BELT RETRACTOR
EP2629616A4 (en)	2014-03-26	SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2173197T3 (da)	2019-09-23	Fremgangsmåde
EP2595966A4 (en)	2015-12-09	SYNTHESIS OF CYCLOPENTACHINAZOLINES
IT1400080B1 (it)	2013-05-17	Disposizione di esca
FR2956419B1 (fr)	2015-01-16	Elements de construction calorifuges
FR2955136B1 (fr)	2012-01-20	Arret de vantail
FI9141U1 (fi)	2011-03-15	Apuväline
UY33133A (es)	2011-07-29	Nuevos derivados de piridazina